Endothelium and regulation of coagulation

David Stern, C. Esposito, H. Gerlach, M. Gerlach, J. Ryan, D. Handley, P. Nawroth

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Endothelial cells form the luminal vascular surface and thus have a central role in the regulation of coagulation. One important way in which endothelial cells control the clotting system is by regulating the expression of binding sites for anticoagulant and procoagulant factors on the cell surface. In the quiescent state, endothelial cells maintain blood fluidity by promoting the activity of numerous anticoagulant pathways, including the protein C/protein S pathway. After activation, as can be brought about by cytokines, the balance of endothelial properties can be tipped to favor clot formation through coordinated induction of procoagulant and suppression of anticoagulant mechanisms. Tumor necrosis factor suppresses the endothelial anticoagulant cofactor thrombomodulin and induces expression of the procoagulant cofactor tissue factor. Working in concert, these changes can allow fibrin formation to proceed in an inflamed focus but maintain blood fluidity in the surrounding area of normal vasculature. Recent studies suggest that similar changes in endothelial coagulant properties can be induced by advanced glycosylation end products, proteins modified by glucose that accumulate in the vasculature at a rapid rate in diabetic subjects, indicating the potential relevance of these mechanisms in diabetic vascular disease.

Original languageEnglish (US)
Pages (from-to)160-166
Number of pages7
JournalDiabetes Care
Volume14
Issue number2
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Anticoagulants
Endothelium
Endothelial Cells
Thrombomodulin
Diabetic Angiopathies
Coagulants
Advanced Glycosylation End Products
Protein S
Thromboplastin
Protein C
Fibrin
Blood Vessels
Tumor Necrosis Factor-alpha
Binding Sites
Cytokines
Glucose
Proteins

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Stern, D., Esposito, C., Gerlach, H., Gerlach, M., Ryan, J., Handley, D., & Nawroth, P. (1991). Endothelium and regulation of coagulation. Diabetes Care, 14(2), 160-166. https://doi.org/10.2337/diacare.14.2.160

Endothelium and regulation of coagulation. / Stern, David; Esposito, C.; Gerlach, H.; Gerlach, M.; Ryan, J.; Handley, D.; Nawroth, P.

In: Diabetes Care, Vol. 14, No. 2, 01.01.1991, p. 160-166.

Research output: Contribution to journalArticle

Stern, D, Esposito, C, Gerlach, H, Gerlach, M, Ryan, J, Handley, D & Nawroth, P 1991, 'Endothelium and regulation of coagulation', Diabetes Care, vol. 14, no. 2, pp. 160-166. https://doi.org/10.2337/diacare.14.2.160
Stern D, Esposito C, Gerlach H, Gerlach M, Ryan J, Handley D et al. Endothelium and regulation of coagulation. Diabetes Care. 1991 Jan 1;14(2):160-166. https://doi.org/10.2337/diacare.14.2.160
Stern, David ; Esposito, C. ; Gerlach, H. ; Gerlach, M. ; Ryan, J. ; Handley, D. ; Nawroth, P. / Endothelium and regulation of coagulation. In: Diabetes Care. 1991 ; Vol. 14, No. 2. pp. 160-166.
@article{b0f3c1d9c54d4086984ec3da4e857e9e,
title = "Endothelium and regulation of coagulation",
abstract = "Endothelial cells form the luminal vascular surface and thus have a central role in the regulation of coagulation. One important way in which endothelial cells control the clotting system is by regulating the expression of binding sites for anticoagulant and procoagulant factors on the cell surface. In the quiescent state, endothelial cells maintain blood fluidity by promoting the activity of numerous anticoagulant pathways, including the protein C/protein S pathway. After activation, as can be brought about by cytokines, the balance of endothelial properties can be tipped to favor clot formation through coordinated induction of procoagulant and suppression of anticoagulant mechanisms. Tumor necrosis factor suppresses the endothelial anticoagulant cofactor thrombomodulin and induces expression of the procoagulant cofactor tissue factor. Working in concert, these changes can allow fibrin formation to proceed in an inflamed focus but maintain blood fluidity in the surrounding area of normal vasculature. Recent studies suggest that similar changes in endothelial coagulant properties can be induced by advanced glycosylation end products, proteins modified by glucose that accumulate in the vasculature at a rapid rate in diabetic subjects, indicating the potential relevance of these mechanisms in diabetic vascular disease.",
author = "David Stern and C. Esposito and H. Gerlach and M. Gerlach and J. Ryan and D. Handley and P. Nawroth",
year = "1991",
month = "1",
day = "1",
doi = "10.2337/diacare.14.2.160",
language = "English (US)",
volume = "14",
pages = "160--166",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Endothelium and regulation of coagulation

AU - Stern, David

AU - Esposito, C.

AU - Gerlach, H.

AU - Gerlach, M.

AU - Ryan, J.

AU - Handley, D.

AU - Nawroth, P.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Endothelial cells form the luminal vascular surface and thus have a central role in the regulation of coagulation. One important way in which endothelial cells control the clotting system is by regulating the expression of binding sites for anticoagulant and procoagulant factors on the cell surface. In the quiescent state, endothelial cells maintain blood fluidity by promoting the activity of numerous anticoagulant pathways, including the protein C/protein S pathway. After activation, as can be brought about by cytokines, the balance of endothelial properties can be tipped to favor clot formation through coordinated induction of procoagulant and suppression of anticoagulant mechanisms. Tumor necrosis factor suppresses the endothelial anticoagulant cofactor thrombomodulin and induces expression of the procoagulant cofactor tissue factor. Working in concert, these changes can allow fibrin formation to proceed in an inflamed focus but maintain blood fluidity in the surrounding area of normal vasculature. Recent studies suggest that similar changes in endothelial coagulant properties can be induced by advanced glycosylation end products, proteins modified by glucose that accumulate in the vasculature at a rapid rate in diabetic subjects, indicating the potential relevance of these mechanisms in diabetic vascular disease.

AB - Endothelial cells form the luminal vascular surface and thus have a central role in the regulation of coagulation. One important way in which endothelial cells control the clotting system is by regulating the expression of binding sites for anticoagulant and procoagulant factors on the cell surface. In the quiescent state, endothelial cells maintain blood fluidity by promoting the activity of numerous anticoagulant pathways, including the protein C/protein S pathway. After activation, as can be brought about by cytokines, the balance of endothelial properties can be tipped to favor clot formation through coordinated induction of procoagulant and suppression of anticoagulant mechanisms. Tumor necrosis factor suppresses the endothelial anticoagulant cofactor thrombomodulin and induces expression of the procoagulant cofactor tissue factor. Working in concert, these changes can allow fibrin formation to proceed in an inflamed focus but maintain blood fluidity in the surrounding area of normal vasculature. Recent studies suggest that similar changes in endothelial coagulant properties can be induced by advanced glycosylation end products, proteins modified by glucose that accumulate in the vasculature at a rapid rate in diabetic subjects, indicating the potential relevance of these mechanisms in diabetic vascular disease.

UR - http://www.scopus.com/inward/record.url?scp=0025793699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025793699&partnerID=8YFLogxK

U2 - 10.2337/diacare.14.2.160

DO - 10.2337/diacare.14.2.160

M3 - Article

VL - 14

SP - 160

EP - 166

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 2

ER -